CEL-SCI Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

CEL-SCI's earnings have been declining at an average annual rate of -2.2%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 72.6% per year.

Anahtar bilgiler

-2.2%

Kazanç büyüme oranı

6.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranı-72.6%
Özkaynak getirisi-343.5%
Net Marjn/a
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

Apr 29
Market Sentiment Around Loss-Making CEL-SCI Corporation (NYSEMKT:CVM)

We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

Mar 01
We Think CEL-SCI (NYSEMKT:CVM) Can Afford To Drive Business Growth

What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Jan 25
What Does CEL-SCI's (NYSEMKT:CVM) CEO Pay Reveal?

Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

Dec 21
Breakeven On The Horizon For CEL-SCI Corporation (NYSEMKT:CVM)

Gelir ve Gider Dağılımı

CEL-SCI nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NYSEAM:CVM Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 240-2990
31 Mar 240-3090
31 Dec 230-3190
30 Sep 230-3290
30 Jun 230-3490
31 Mar 230-3590
31 Dec 220-37100
30 Sep 220-38110
30 Jun 220-37110
31 Mar 220-36120
31 Dec 210-37130
30 Sep 210-37130
30 Jun 210-34130
31 Mar 210-35130
31 Dec 201-33120
30 Sep 201-30120
30 Jun 201-30110
31 Mar 201-32100
31 Dec 190-2990
30 Sep 190-2280
30 Jun 191-3260
31 Mar 191-2660
31 Dec 181-2450
30 Sep 180-3260
30 Jun 180-2270
31 Mar 180-2070
31 Dec 170-2470
30 Sep 170-1460
30 Jun 170-1080
31 Mar 170-1080
31 Dec 160-1070
30 Sep 160-1280
30 Jun 160-2070
31 Mar 160-2180
31 Dec 151-25100
30 Sep 151-35140
30 Jun 151-32150
31 Mar 150-30150
31 Dec 140-31140
30 Sep 140-28110
30 Jun 140-2380
31 Mar 140-257-5
31 Dec 130-1270

Kaliteli Kazançlar: CVM is currently unprofitable.

Büyüyen Kar Marjı: CVM is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CVM is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.

Büyüme Hızlandırma: Unable to compare CVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: CVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: CVM has a negative Return on Equity (-343.45%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin